JPWO2022221726A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022221726A5
JPWO2022221726A5 JP2023562872A JP2023562872A JPWO2022221726A5 JP WO2022221726 A5 JPWO2022221726 A5 JP WO2022221726A5 JP 2023562872 A JP2023562872 A JP 2023562872A JP 2023562872 A JP2023562872 A JP 2023562872A JP WO2022221726 A5 JPWO2022221726 A5 JP WO2022221726A5
Authority
JP
Japan
Prior art keywords
days
hours
therapeutic agent
subject
cell preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514163A5 (https=
JP2024514163A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025115 external-priority patent/WO2022221726A2/en
Publication of JP2024514163A publication Critical patent/JP2024514163A/ja
Publication of JP2024514163A5 publication Critical patent/JP2024514163A5/ja
Publication of JPWO2022221726A5 publication Critical patent/JPWO2022221726A5/ja
Pending legal-status Critical Current

Links

JP2023562872A 2021-04-16 2022-04-15 Bcma指向性t細胞療法を用いた併用療法 Pending JP2024514163A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163176196P 2021-04-16 2021-04-16
US63/176,196 2021-04-16
PCT/US2022/025115 WO2022221726A2 (en) 2021-04-16 2022-04-15 Combination therapies with bcma-directed t cell therapy

Publications (3)

Publication Number Publication Date
JP2024514163A JP2024514163A (ja) 2024-03-28
JP2024514163A5 JP2024514163A5 (https=) 2025-04-18
JPWO2022221726A5 true JPWO2022221726A5 (https=) 2025-04-18

Family

ID=81846411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562872A Pending JP2024514163A (ja) 2021-04-16 2022-04-15 Bcma指向性t細胞療法を用いた併用療法

Country Status (9)

Country Link
US (1) US20240207310A1 (https=)
EP (1) EP4322959A2 (https=)
JP (1) JP2024514163A (https=)
KR (1) KR20230171468A (https=)
CN (1) CN118201618A (https=)
AU (1) AU2022258832A1 (https=)
CA (1) CA3214683A1 (https=)
IL (1) IL307612A (https=)
WO (1) WO2022221726A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
EP4032552B1 (en) 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
DE112012007250B4 (de) 2012-12-20 2024-10-24 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
WO2015158671A1 (en) 2014-04-14 2015-10-22 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-bcma嵌合抗原受體治療癌症
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
RU2685500C2 (ru) 2014-09-22 2019-04-18 Сакми Кооператива Мекканичи Имола Сочиета' Кооператива Линия для производства индивидуальных изделий последовательно в непрерывном цикле
KR20240135036A (ko) 2014-12-05 2024-09-10 메모리얼 슬로안 케터링 캔서 센터 B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
AU2015357526B2 (en) 2014-12-05 2022-03-17 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
EA036379B1 (ru) 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
CN106014789A (zh) 2016-06-25 2016-10-12 郭远军 一种悬吊式一体化反装斜击式水轮发电机及其做功方法
BR112020010579A2 (pt) * 2017-11-30 2020-11-10 Novartis Ag receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
CA3105813A1 (en) * 2018-07-11 2020-01-16 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
WO2020097403A1 (en) * 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
CN116157125A (zh) * 2020-04-28 2023-05-23 朱诺治疗学股份有限公司 针对bcma的t细胞疗法与免疫调节化合物的组合

Similar Documents

Publication Publication Date Title
JP6970099B2 (ja) ガンの処置のための方法及び医薬組成物
JP2025138634A (ja) B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
JP7384835B2 (ja) Cd3に特異的な抗体及びその使用
JP2020522495A (ja) 抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物
CN111032085A (zh) 用于癌症治疗或预防的免疫检查点分子拮抗剂和rank-l(nf-kb配体)拮抗剂的组合或其双特异性结合分子及其用途
JP2019514846A (ja) 免疫チェックポイントモジュレーターとのt細胞リダイレクティング多機能抗体の組み合わせとその使用
CN107708741A (zh) 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
JP2025106512A (ja) 調節性t細胞及びその使用
CN115916199A (zh) 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
JP2021520201A (ja) 抗cd27抗体およびその使用
US20250340634A1 (en) Dosage regimens for anti-cd19 agents and uses thereof
US20220227876A1 (en) Rank antagonists and uses thereof
AU2023375177A1 (en) Methods of treating cancers
TW202131950A (zh) 依序抗cd19療法
IL254335B (en) Isolated peptides derived from the dimerization regions of b7
JPWO2021163389A5 (https=)
JPWO2022221726A5 (https=)
WO2023146394A1 (en) Combination therapy for the treatment of cancer
US20230172923A1 (en) Methods of treating cytokine-related adverse events
US20260102490A1 (en) Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma
JPWO2021222330A5 (https=)
WO2025089399A1 (ja) インターロイキン7受容体(il-7r)に対する抗体および当該抗体を含む抗体薬物コンジュゲート(adc)
WO2026034573A1 (ja) Cd320に結合する抗体およびその断片、並びに前記抗体を含む抗体薬物コンジュゲート
JP2026510808A (ja) ヒト抗体を標的とするメラノーマとその治療方法
JPWO2023081735A5 (https=)